Emavusertib|1801344-14-8|(CA-4948)-陌孚医药/Medlife

您当前的位置：

Emavusertib (Synonyms: CA-4948)

目录号: PL03451 纯度: ≥99%

CAS No. :1801344-14-8

商品编号	规格	价格	会员价
PL03451-5mg	5mg	¥939.64	请登录
PL03451-10mg	10mg	¥1211.64	请登录
PL03451-25mg	25mg	¥2349.09	请登录
PL03451-50mg	50mg	¥4327.27	请登录
PL03451-100mg	100mg	¥7170.91	请登录
PL03451-200mg	200mg	询价	询价
PL03451-500mg	500mg	询价	询价
PL03451-10mM*1mLinDMSO	10mM*1mLinDMSO	¥1013.82	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Emavusertib
英文名称	Emavusertib
英文别名	(R)-N-(5-(3-Hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;N-[5-[(3R)-3-Hydroxypyrrolidin-1-yl]-2-morpholin-4-yl-[1,3]oxazolo[4,5-b]pyridin-6-yl]-2-(2-methylpy;CA-4948;Emavusertib;MH5DMF9JKY;CA4948;4-Oxazolecarboxamide, N-[5-[(3R)-3-hydroxy-1-pyrrolidinyl]-2-(4-morpholinyl)oxazolo[4,5-b]pyridin-6-yl]-2-(2-methyl-4-pyridinyl)-;N-[5-[(3R)-3-hydroxypyrrolidin-1-yl]-2-morpholin-4-yl-[1,3]oxazolo[4,5-b]pyridin-6-yl]-2-(2-methylpyridin-4-yl)-1,3-oxazole-4-carboxamide;2-(2-methylpyridin-4-yl)-N-[2
Cas No.	1801344-14-8
分子式	C₂₄H₂₅N₇O₅
分子量	491.50
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情

Emavusertib (CA-4948) 是一种有效的 IRAK4/FLT3 抑制剂，具有抗肿瘤活性。

生物活性

Emavusertib (CA-4948) is a potent IRAK4/FLT3 inhibtor with anti-tumor activity.

性状

Solid

IC50 & Target[1][2]

IRAK4 FLT3

体外研究(In Vitro)

Emavusertib (CA-4948) is over 500-fold more selective for IRAK-4 compared to IRAK-1. Emavusertib reduces TNF-α, IL-1β, IL-6 and IL-8 release from TLR-Stimulated THP-1 Cells with an IC50 <250 nM. Emavusertib also has antiproliferative activity due to inhibition of receptor-type tyrosine-protein kinase FLT3. has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

Emavusertib (CA-4948) shows anti-tumor activity in animal models including tumors containing MyD88 gene mutations. Emavusertib shows antileukemic activity in mouse models of FLT3 wild-type and FLT3 mutated acute myeloid leukemia (AML). has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder -20°C 3 years；4°C 2 years

ClinicalTrial

参考文献

[1]. Wiese MD, et al. Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 2020 Apr 17:1-8.

溶解度数据	In Vitro: DMSO : 50 mg/mL (101.73 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation